



BRIAN SANDOVAL  
Governor

STATE OF NEVADA  
DEPARTMENT OF HEALTH AND HUMAN SERVICES  
DIVISION OF HEALTH CARE FINANCING AND POLICY  
1100 E. William Street, Suite 101  
Carson City, Nevada 89701  
(775) 684-3676 • Fax (775) 687-3893

RICHARD WHITLEY, MS  
Director

MARTA JENSEN  
Acting Administrator

## NOTICE OF PUBLIC MEETING – DRUG USE REVIEW BOARD

### AGENDA

**Date of Posting:** October 7, 2015

**Date of Meeting:** November 5, 2015 at 5:15 PM

**Name of Organization:** The State of Nevada, Department of Health and Human Services, Division of Health Care Financing and Policy (DHCFP), Drug Use Review Board (DUR)

**Place of Meeting:** Best Western Plus Airport Plaza Hotel  
1981 Terminal Way  
Reno, NV 89502  
Phone: (775) 348-6370

**Webinar Pre-Registration:** **\*\*Must Pre-Register\*\***  
  
<https://catamaranrx.webex.com/catamaranrx/j.php?MTID=e8c7c4a334adb6aa25d6febeb9e9d9a0c>  
  
Once you have registered for the meeting, you will receive an email message confirming your registration. This message will provide the information that you need to join the meeting.

**Webinar Event:** <https://catamaranrx.webex.com/catamaranrx/j.php?MTID=e8c7c4a334adb6aa25d6febeb9e9d9a0c>

**Event Number:** 749 358 430  
  
Click "Join Now"  
  
Follow the instructions that appear on your screen to join the teleconference.

**Teleconference:** (855) 210-1642

**Access Code:** 3844816

## AGENDA

### 1. Call to Order and Roll Call

### 2. Public Comment on Any Matter on the Agenda

### 3. Administrative

- a. **For Possible Action:** Review and Approve Meeting Minutes from September 3, 2015.
- b. Status Update by DHCFP
  - i. Public Comment

### 4. Board Action

- a. **For Possible Action:** Discussion on Lock-in Program proposed changes to criteria
  - i. Public comment on the Lock-in Program criteria process and policy
  - ii. Discussion by the Board and review of utilization data, current policy and the Pharmacy Lock-In Referral to Therapy
  - iii. Possible adoption of updated Lock-in policy and criteria

### 5. Clinical Presentations

- a. **For Possible Action:** Discussion and possible adoption of updated prior authorization criteria for the addition of daclatasvir (Daklinza®) and ombitasvir/paritaprevir/ritonavir (Technivie®) to the current Hepatitis C criteria.
  - i. Public comment on adoption of policy.
  - ii. Presentation of utilization and clinical information.
  - iii. Discussion by the Board and review of utilization data.
  - iv. Possible adoption of prior authorization criteria/policy.
- b. **For Possible Action:** Discussion and possible adoption of prior authorization criteria for paliperidone palmitate (Invega Trinza®).
  - i. Public comment on proposed clinical prior authorization criteria.
  - ii. Presentation of utilization and clinical information.
  - iii. Discussion by the Board and review of utilization data.
  - iv. Proposed adoption of updated prior authorization criteria.
- c. **For Possible Action:** Discussion and possible adoption of prior authorization criteria for alirocumab (Praluent®).
  - i. Public Comment on proposed clinical prior authorization criteria.
  - ii. Presentation of utilization and clinical information.

- iii. Discussion by the Board and review of utilization data.
- iv. Proposed adoption of updated prior authorization criteria
- d. **For Possible Action:** Discussion and possible adoption of prior authorization criteria for lumacaftor/ivacaftor (Orkambi®)
  - i. Public comment on proposed clinical prior authorization criteria.
  - ii. Presentation of utilization and clinical information.
  - iii. Discussion by Board and review of utilization data.
  - iv. Proposed adoption of updated prior authorization criteria.
- e. **For Possible Action:** Discussion and possible adoption of updated prior authorization criteria for the addition of riloncept (Arcalyst®), secukinumab (Cosntyx®) and Canakinumab (Ilaris®) to the current immunomodulator criteria.
  - i. Public comment on proposed clinical prior authorization criteria.
  - ii. Presentation of utilization and clinical information.
  - iii. Discussion by Board and review of utilization data.
  - iv. Proposed adoption of updated prior authorization criteria.
- f. **For Possible Action:** Discussion and possible adoption of prior authorization criteria for sacubitril/valsartan (Entresto®)
  - i. Public comment on proposed clinical prior authorization criteria.
  - ii. Presentation of utilization and clinical information.
  - iii. Discussion by Board and review of utilization data.
  - iv. Proposed adoption of updated prior authorization criteria.

## 6. Public Comment on any DUR Board Requested Report

## 7. DUR Board Requested Reports

- a. Report on diabetic patient compliance for blood glucose monitoring receiving insulin and possible hospitalizations due to lack of monitoring.
  - i. Discussion by the Board and review of utilization data.
- b. Brand products dispensed where a generic is available
  - i. Discussion by the Board and review of utilization data.
- c. Midazolam Syrup utilization
  - i. Discussion by the Board and review of utilization data.
- d. Hydrocodone Product utilization
  - i. Discussion by the Board and review of utilization data.

## **8. Public Comment on any Standard DUR Report**

## **9. Standard DUR Reports**

- a. Review of Prescribing/Program Trends.
  - i. Top 10 Therapeutic Classes for Q1 2015, Q2 2015 and Q3 2015 (by Payment and by Claims).
  - ii. Top 50 Drugs of Q1 2015, Q2 2015 and Q3 2015 (by Payment and by Claims).
- b. Concurrent Drug Utilization Review (ProDUR)
  - i. Review of Q1 2015, Q2 2015 and Q3 2015.
  - ii. Review of Top Encounters by Problem Type.
- c. Retrospective Drug Utilization Review (RetroDUR)
  - i. Status of previous quarter.
  - ii. Status of current quarter.
  - iii. Review and discussion of responses.

## **7. Closing Discussion**

- a. Public comments on any subject.
- b. Date and location of the next meeting.
  - i. Discussion of the time of the next meeting.
- c. Adjournment.

**PLEASE NOTE:** Items may be taken out of order at the discretion of the chairperson. Items may be combined for consideration by the public body. Items may be pulled or removed from the agenda at any time. If an action item is not completed within the time frame that has been allotted, that action item will be continued at a future time designated and announced at this meeting by the chairperson. All public comment may be limited to 5 minutes.

This notice and agenda have been posted at <http://dhcfp.nv.gov> and <http://notice.nv.gov>

---

Notice of this meeting will be available on or after the date of this notice at the DHCFP Web site [www.dhcfp.nv.gov](http://www.dhcfp.nv.gov), Carson City Central office and Las Vegas DHCFP. The agenda posting of this meeting can be viewed at the following locations: Nevada State Library; Carson City Library; Churchill County Library; Las Vegas Library; Douglas

October 7, 2015

Page 5

**County Library; Elko County Library; Lincoln County Library; Lyon County Library; Mineral County Library; Tonopah Public Library; Pershing County Library; Goldfield Public Library; Eureka Branch Library; Humboldt County Library; Lander County Library; Storey County Library; Washoe County Library; and White Pine County Library and may be reviewed during normal business hours.**

**If requested in writing, a copy of the meeting materials will be mailed to you. Requests and/or written comments may be sent to Robyn Heddy at the Division of Health Care Financing and Policy, 1100 E. William Street, Suite 101, Carson City, NV 89701, at least 3 days before the public hearing.**

**All persons that have requested in writing to receive the Public Hearings agenda have been duly notified by mail or e-mail.**

**Note: We are pleased to make accommodations for members of the public who have disabilities and wish to attend the meeting. If special arrangements are necessary, notify the Division of Health Care Financing and Policy as soon as possible and at least ten days in advance of the meeting, by e-mail at [robyn.heddy@dhefp.nv.gov](mailto:robyn.heddy@dhefp.nv.gov) in writing, at 1100 East William Street, Suite 101, Carson City, Nevada 89701 or call Robyn Heddy at (775) 684-3678.**